Active broad-market exchange-traded funds at the close of
Friday's regular session:
SPDR S&P 500 (
iShares S&P 500 (
PowerShares QQQ (
iShares Russell 2000 (
iShares Russell 1000 Growth (
iShares MSCI Emerging Markets Index (EEM): +0.57%
United States Oil Fund (USO): +2.12%
SPDR Gold Shares (GLD): +0.77%
Select Financial Sector SPDRS (XLF): -0.10%
Broad Market Indicators
Most broad-market exchange-traded funds, including SPY, IWM, IVV
are mixed. Actively traded PowerShares QQQ (
) was up 0.03%.
U.S. futures are also mixed in light pre-market trading, with no
economic data releases on tap. Investors will be awaiting new
Federal Reserve Chief Janet Yellen's testimony before the House
Financial Services Committee Tuesday. In earnings news, Hasbro
(HAS), Sohu.com (SOHU) and Dick's Sporting Goods (DKS) are among
Power Play: Consumer
Consumer Staples Select Sector SPDR (XLP), Vanguard Consumer
Staples ETF (VDC) and iShares Dow Jones US Consumer Goods (IYK)
were unchanged pre-market after a firmer session Friday.
In stocks news, Hasbro, Inc. (HAS) was down more than 2% after
reporting adjusted diluted EPS for Q4 2013 of $1.12 versus $1.20
last year. The Street was looking for diluted EPS of $1.24,
according to Capital IQ. Revenues were flat at $1.28 billion
compared to last year and in line with the Capital IQ consensus.
Furthermore, the company set a quarterly cash dividend of $0.43 per
common share, up 8% from the previous quarterly dividend paid. The
current dividend will be distributed on May 15 to shareholders of
record at the close of business on May 1.
Winners and Losers
Select Financial Sector SPDRs (XLF) was leaning into positive
territory pre-bell. Direxion Daily Financial Bull 3X shares (FAS)
gained 0.8%. Its bearish counterpart, FAZ, fell 0.18%.
Among financial stocks, Barclays (BCS) was up more than 1% in
Monday's pre-bell session despite a news story that broke over the
weekend saying the bank had suffered a data leak in which thousands
of its customer details were stolen and sold to brokers. Barclays
also said this morning that it earned adjusted pretax profit of
GBP5.2 billion in 2013, below estimates for GBP5.4 billion. It will
release its full results tomorrow morning.
Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US
Technology ETF (IYW), iShares S&P North American Technology ETF
(IGM) and iShares S&P North American Technology-Software Index
(IGV) were firmer. SPDR S&P International Technology Sector ETF
(IPK) all closed higher on Friday, but were unchanged
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) and
Semiconductor Sector Index Fund (SOXX) were also flat after posting
In stocks news, AutoNavi (AMAP) was up 29% in Monday's
pre-market after Alibaba offered to take the company private for
$21 per ADS.
Dow Jones U.S. Energy Fund (IYE) was flat, and Energy Select
Sector SPDR (XLE) slipped 0.05%.
In corporate news, Gran Tierra Energy Inc. (GTE, GTE.TO) said
that after producing a record volume of oil last year, its oil
reserves grew at year-end 2013 in all categories. It said total
proved oil and gas reserves net after royalty increased 4% year
over year to 42.1 million barrels of oil equivalent (MMBOE). Total
Proved plus Probable reserves net after royalty were up 99% to
111.9 MMBOE from last year. Total Proved plus Probable plus
Possible reserves net after royalty jumped 113% to 183.9 MMBOE.
Crude fell 0.32%; United States Oil Fund (USO) flat. Natural gas
fell 1.74% and United States Natural Gas Fund (UNG) dropped
Gold rose 1.05% and silver fell 1.60%. Among rare metal funds,
SPDR Gold Trust (GLD) rose 0.74% and iShares Silver Trust (SLV)
edged up 1.30%.
Health Care SPDR (XLV), Vanguard Health Care ETF (VHT) and
iShares Dow Jones US Healthcare (IYH) were all flat after gaining
on Friday. Biotech ETF iShares NASDAQ Biotechnology Index (IBB) was
slipping into the red, pre-bell.
In corporate news, Regeneron Pharmaceuticals (REGN) and Bayer
Healthcare said data from its Phase 3 trial on the Eylea drug to
treat diabetic macular edema showed a sustained improvement at week
100. The drug was well tolerated. Regeneron has the exclusive
rights to the drug in the U.S.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.